Extensive weight loss can reduce immune age by altering IgG N-glycosylation

Valentina L Greto[1]*, Ana Cvetko[2]*, Tamara Štambuk[3]*, Niall J Dempster[4], Domagoj Kifer[2], Helena Deriš[3], Ana Cindrić[3], Frano Vučković[3], Mario Falchi[5], Richard S Gillies[6], Jeremy W Tomlinson[4], Olga Gornik[2,3], Bruno Sgromo[6], Tim D Spector[5], Cristina Menni[5]*, Alessandra Geremia[1]*, Carolina V Arancibia- Cárcamo[1]*, Gordan Lauc[2,3]*

[1]Translational Gastroenterology Unit, Nuffield Department of Medicine, University of Oxford, United Kingdom

[2]Faculty of Pharmacy and Biochemistry, University of Zagreb, Zagreb, Croatia

[3]Genos Glycoscience Research Laboratory, Zagreb, Croatia

[4]Oxford Centre for Diabetes, Endocrinology and Metabolism, Radcliffe Department of Medicine, University of Oxford, United Kingdom

[5]The Department of Twin Research, King's College London, St Thomas' Hospital, London, United Kingdom

[6]Department of Upper GI Surgery, Oxford University Hospitals, United Kingdom

*The authors equally contributed to this work

Corresponding author:

Gordan Lauc

glauc@pharma.hr

Faculty of Pharmacy and Biochemistry, University of Zagreb

A. Kovačića 1, 10 000 Zagreb, Croatia

ABSTRACT

Background

Obesity represents a global health threat, and is associated not only with exponentially increased cardiometabolic morbidity and mortality, but with adverse clinical outcomes in patients infected with SARS-CoV-2 as well. Enzymatic attachment of complex oligosaccharides to proteins (glycosylation) is highly responsive to numerous (patho)physiological conditions and ageing, which is perhaps best exemplified on IgG. The prospect of immune age reduction, by reverting induced glycosylation changes through metabolic intervention, opens many possibilities. Herein, we have investigated whether weight loss interventions affect inflammation- and ageing-related glycosylation alterations, in a longitudinal cohort of bariatric-surgery patients. To support potential findings, BMI-related glycosylation changes were monitored in a longitudinal TwinsUK cohort.

Methods

IgG and plasma N-glycans were chromatographically profiled in 37 obese patients, subjected to low-calorie diet and then to bariatric surgery, across multiple timepoints. Similarly, plasma glycome was analysed in 1,680 TwinsUK participants and longitudinally monitored during a 20-year follow-up.

Findings

Low-calorie diet induced marked increase in low branched and significant decrease in highly branched, more complex plasma N-glycans – the change opposite to the one typically observed in inflammatory conditions. Bariatric surgery resulted in extensive, gradual alterations in IgG glycome, that accompanied progressive weight loss during one year follow-up. We observed significant increase in digalactosylated and sialylated, and substantial decrease in agalactosylated and core fucosylated IgG glycans. In general, such IgG glycan profile is associated with a younger biological age and reflects enhanced anti-inflammatory IgG potential. The TwinsUK cohort replicated weight loss-associated agalactosylation decrease and digalactosylation increase, estimated through BMI decrease over a 20-year-period.

Interpretation

Altogether, these findings highlight that weight loss substantially affects both plasma and IgG N-glycosylation, resulting in improved biological and immune age.

GRAPHICAL ABSTRACT



HIGHLIGHTS

- Obesity is associated to circulating pro-inflammatory high branched N-glycans and IgG agalactosylation
- High branching of N-glycans from total plasma proteins decreases after 3-week low-calorie diet
- IgG galactosylation and sialylation increase after bariatric surgery-induced weight loss
- Decrease of BMI over time is associated with increased IgG galactosylation and improvement of biological age

KEYWORDS

N-glycosylation; bariatric surgery; weight loss; imunoglobulin G; COVID-19; biological age

INTRODUCTION

The global prevalence of obesity has risen dramatically, to the point that it is now considered a pandemic (1). In the current collision with the emergent coronavirus disease (COVID-19 pandemic), there is a strong association of obesity and older age with COVID-19 complications and severity (2). According to the World Health Organization, over 650 million individuals are obese, accounting for the 13% of the world's adult population. Obesity confers a risk for metabolic syndrome, contributing to type 2 diabetes and cardiovascular disease (CVD) development (3). Metabolic syndrome is linked to a chronic systemic low-grade inflammation, which contributes to the aging of the immune system denoted as inflammaging (4,5). Obesity-related inflammaging results in impaired innate and adaptive immune function, and is characterized by high serum levels of IL-6, TNF-α and CRP (6). Moreover, this persistent inflammatory state may potentially lead to increased viral shedding and to delayed, blunted antiviral responses to SARS-CoV-2 infection (7,8).

Changes in protein N-glycosylation are one of the hallmarks of inflammaging (5,8). The human circulating N-glycome represents the entire set of glycans that are covalently attached to plasma proteins through a nitrogen on an asparagine residue. N-glycans are essential for life and are involved in many physiological processes (9), including signal transduction, protein trafficking and folding, receptor regulation and cell adhesion. Glycosylation has a fundamental role in the innate and adaptive immune responses, accentuated by the fact that all five classes of immunoglobulins (Ig) bear N-glycans. In this regard, IgG is probably the most investigated glycoprotein, whose effector functions are controlled by its Fc-bound glycans (10).

Inter-individual differences in the pace of biological ageing is an intriguing concept that tries to explain why some people stay healthy until very late chronological age, while others age faster and have shorter life expectancy. The same may apply for the risk of severe COVID-19. Progressive age-related changes of IgG glycosylation have been extensively studied (9,11,12), and the GlycanAge model has been proposed to express the difference between chronological ageing and IgG glycome ageing (13). The "age" of the IgG glycome might be estimated through the levels of agalactosylated species, which are increasing with ageing and are associated with enhanced immune activation (14). The opposite applies for digalactosylated IgG glycoforms, which are usually related to a younger age. Besides age-related changes, specific IgG glycosylation patterns have been already associated with CVD risk score and subclinical atherosclerosis in two large independent UK cohorts (15). Moreover, a prospective follow-up

of the EPIC-Potsdam cohort confirmed that changes in plasma N-glycome composition are predictive of future CVD events, with comparable predictive power to the American Heart Association (AHA) score in men and even better predictive power in women (16). The link between an "old", proinflammatory IgG N-glycome and hypertension has also been profoundly studied (17–19), and similar IgG glycosylation patterns were associated with increased body mass index (BMI) and measures of central adiposity (20,21).

Studies on mouse models further corroborate the importance of differential IgG glycoforms in CVD pathogenesis. Namely, it has been shown that hyposialylated IgG (corresponding to an "old" IgG glycome) can induce obesity-related hypertension and insulin resistance in B-cell-deficient mice, through activation of the endothelial FcγRIIB (22,23). These findings indicate that the IgG N-glycome could represent more than a biomarker of inflammation and aging, since distinctive IgG glycoforms act as effector molecules in certain pathologies. Furthermore, supplementation with *N*-acetylmannosamine (ManNAc), a precursor of sialic acid, protects obese mice from hypertension and insulin resistance induction by reverting an "old" IgG N-glycome into a "young" one (23,24). However, studies exploring the possibilities of converting an "old" IgG glycome into a "young" one by metabolic intervention in humans are limited. Of note, only one small study indicated that high-intensity interval training can "rejuvenate" the IgG N-glycome (25).

Finally, severe obesity can be resolved only through bariatric surgery and subsequent weight loss (26). The resulting weight loss impacts energy balance and metabolism, contributing to the increased insulin response, improved glycaemic control and reduction of total body fat, leading to decreased CVD risk and mortality (27). In this study we aimed to determine whether weight loss affects glycan markers related to inflammation and ageing, in a longitudinally-monitored cohort of obese individuals undergoing low-calorie diet and then bariatric surgical interventions. In order to support potential findings, we also investigated the BMI-related glycosylation changes in a longitudinal TwinsUK cohort. The analysis of samples obtained from the largest longitudinal twins cohort in the UK allowed us to observe the changes of BMI in relation to the IgG N-glycosylation alterations over time.

METHODS

Study populations

Bariatric cohort. The cohort included 37 participants, recruited at Oxford University Hospitals to the Gastrointestinal Illnesses study (Ref: 16/YH/0247). All patients were characterised by metabolic status and medical history. Bariatric patients were considered eligible in accordance to National Institute for Health and Care Excellence (NICE) and local guidelines. The choice of bariatric operation was decided according to the Oxford Bariatric Unit regular practice. Patients with a history of alcoholism and/or ongoing anticoagulant treatment were excluded. Patients were also excluded in case of pregnancy, active substance abuse or uncontrolled psychiatric condition including eating disorders. Participants were sampled at baseline and subjected to 3-week low calorie carbohydrate-restricted diet (900 cal, maximum 100 g of carbohydrates per day), followed by bariatric surgery. The sequential follow-up timepoints included the day of the surgery (baseline), after 6.54 ± 3.4 months (mean ± IQR) and 12.47 ± 6.55 months post-op. Characteristics of the bariatric cohort are shown in Table 1.

Table 1 Demographic characteristics of the bariatric cohort

Characteristics	*Bariatric cohort*				
Total No. of participants (N)	37				
No. of participants Sleeve Gastrectomy (SG), N (%)	25 (68%)				
No. Roux-en-Y Gastric Bypass RYGB N (%)	12 (32%)				
No. of participants each timepoint (N)	Pre-op low-calorie diet		Time of surgery	1st post-op timepoint	2nd post-op timepoint
	8		37	30	24
BMI* each timepoint, mean ± SD, kg/m2	Before diet	End of diet	Time of surgery	1st post-op timepoint	2nd post-op timepoint
	48.53 ± 4.13	46.60± 4.21	46.21 ± 4.75	36.01 ± 5.07	32.82 ± 5.17
Female, sex, N (%)	33 (89%)				
Type 2 diabetes, N (%)	6 (16%)				

*BMI reference values: <18.5 (underweight), 18.5–24.9 (normal weight), 25–29.9 (overweight), >30 (obese).

TwinsUK cohort. We have analysed a total of 6,032 plasma samples from 2,146 participants of the TwinsUK study, collected at multiple timepoints over a 20 year-period (28). These included 1,865 individuals sampled at 3 timepoints, 156 individuals sampled at 2 timepoints and 125 individuals sampled only once. Following the plasma N-glycome analysis, glycan data underwent quality control (see *Statistical analysis* section), which decreased the dataset to 5,889 samples (measurements). Out of these 5,889 measurements, we have proceeded with

141 statistical analysis on a subset of 3,742 samples (measurements) which had information on
142 BMI available. Description of the TwinsUK cohort is provided in Table 2.
143
144 **Table 2 Demographic characteristics of the TwinsUK cohort**

Characteristics	*TwinsUK cohort (BMI subset)*
No. of participants (N)	1,680
No. of glycan measurements (N)	3,742
Baseline age, mean ± SD, years	53.23 ± 10.86
Follow up time, mean ± SD, years	7.90 ± 5.66
Female sex, N (%)	1,680 (100)
Baseline BMI, mean ± SD, kg/m^2	25.45 ± 4.53

145
146 **Ethical statement**
147 Ethical approval for the study was obtained by the National Research Ethics Committees of
148 the UK National Health Service (NHS) under the reference number 16/YH/0247. All individuals
149 participating in this study gave written informed consent. The TwinsUK study was approved
150 by NRES Committee London–Westminster, and all twins provided informed written consent.
151 **N-glycome analysis**
152 *Isolation of IgG from human plasma*
153 IgG was isolated from plasma samples by affinity chromatography as described previously
154 (29). In brief, IgG was isolated in a high-throughput manner, using 96-well protein G
155 monolithic plates (BIA Separations, Slovenia), starting from 100 µl of plasma. Plasma was
156 diluted 7× with phosphate buffered saline (PBS; Merck, Germany) and applied to the protein
157 G plate. IgG was eluted with 1 ml of 0.1 M formic acid (Merck, Germany) and immediately
158 neutralized with 1 M ammonium bicarbonate (Acros Organics, USA).
159 *N-glycan release from IgG and total plasma proteins*
160 Isolated IgG samples were dried in a vacuum centrifuge. After drying, IgG was denatured with
161 the addition of 30 µl of 1.33% SDS (w/v) (Invitrogen, USA) and by incubation at 65 °C for 10
162 min. Plasma samples (10 µl) were denatured with the addition of 20 µl of 2% (w/v) SDS
163 (Invitrogen, USA) and by incubation at 65 °C for 10 min. From this point on, the procedure was
164 identical for both IgG and plasma samples. After denaturation, 10 µl of 4% (v/v) Igepal-CA630

(Sigma Aldrich, USA) was added to the samples, and the mixture was shaken 15 min on a plate shaker (GFL, Germany). N-glycans were released with the addition of 1.2 U of PNGase F (Promega, USA) and overnight incubation at 37 °C.

Fluorescent labelling and HILIC SPE clean-up of released N glycans

The released N-glycans were labelled with 2-aminobenzamide (2-AB). The labelling mixture consisted of 2-AB (19.2 mg/ml; Sigma Aldrich, USA) and 2-picoline borane (44.8 mg/ml; Sigma Aldrich, USA) in dimethyl sulfoxide (Sigma Aldrich, USA) and glacial acetic acid (Merck, Germany) mixture (70:30 v/v). To each sample 25 µl of labelling mixture was added, followed by 2 h incubation at 65 °C. Free label and reducing agent were removed from the samples using hydrophilic interaction liquid chromatography solid-phase extraction (HILIC-SPE). After incubation samples were brought to 96% of acetonitrile (ACN) by adding 700 µl of ACN (J.T. Baker, USA) and applied to each well of a 0.2 µm GHP filter plate (Pall Corporation, USA). Solvent was removed by application of vacuum using a vacuum manifold (Millipore Corporation, USA). All wells were prewashed with 70% ethanol (Sigma-Aldrich, St. Louis, MO, USA) and water, followed by equilibration with 96% ACN. Loaded samples were subsequently washed 5× with 96% ACN. N-glycans were eluted with water and stored at − 20 °C until usage.

Hydrophilic interaction liquid chromatography of N glycans

Fluorescently labelled N-glycans were separated by hydrophilic interaction liquid chromatography (HILIC) on Acquity UPLC H-Class instrument (Waters, USA) consisting of a quaternary solvent manager, sample manager and a fluorescence detector, set with excitation and emission wavelengths of 250 and 428 nm, respectively. The instrument was under the control of Empower 3 software, build 3471 (Waters, Milford, USA). Labelled N-glycans were separated on a Waters BEH Glycan chromatography column, with 100 mM ammonium formate, pH 4.4, as solvent A and ACN as solvent B. In the case of IgG N-glycans, separation method used linear gradient of 75–62% acetonitrile at flow rate of 0.4 ml/min in a 27-min analytical run. For plasma protein N-glycans separation method used linear gradient of 70–53% acetonitrile at flow rate of 0.561 ml/min in a 25-min analytical run. The system was calibrated using an external standard of hydrolysed and 2-AB labelled glucose oligomers from which the retention times for the individual glycans were converted to glucose units (GU). Data processing was performed using an automatic processing method with a traditional integration algorithm after which each chromatogram was manually corrected to maintain the same intervals of integration for all the samples. The chromatograms were all separated

in the same manner into 24 peaks (GP1– GP24) for IgG N-glycans and 39 peaks (GP1–GP39) for plasma protein N-glycans and are depicted in Supplementary Figure 1 and Supplementary Figure 2, respectively. Detailed description of glycan structures corresponding to each glycan peak is presented in Supplementary Table 1. Glycan peaks were analysed based on their elution positions and measured in glucose units, then compared to the reference values in the "GlycoStore" database (available at: https ://glyco store .org/) for structure assignment. The amount of glycans in each peak was expressed as a percentage of the total integrated area. For IgG glycans, in addition to 24 directly measured glycan traits, 8 derived traits were calculated, while for plasma glycans, in addition to 39 directly measured glycan traits, 16 derived traits were also calculated. These derived traits average particular glycosylation features, such as galactosylation, fucosylation, bisecting GlcNAc, and sialylation. Formulas for IgG and plasma protein N-glycan derived traits for bariatric cohort are presented in Supplementary Table 2 and Supplementary Table 3, respectively. Derived trait calculations for TwinsUK cohort are presented in Supplementary Table 4.

Statistical analysis

Bariatric cohort. In order to remove experimental variation from the measurements, normalization and batch correction were performed on the UPLC glycan data. To make measurements across samples comparable, normalization by total area was performed. Prior to batch correction, normalized glycan measurements were log-transformed due to right-skewness of their distributions and the multiplicative nature of batch effects. Batch correction was performed on log-transformed measurements using the ComBat method (R package sva (30), where the technical source of variation (which sample was analysed on which plate) was modelled as batch covariate. To correct measurements for experimental noise, estimated batch effects were subtracted from log-transformed measurements.

Longitudinal analysis of patient samples through their observation period was performed by implementing a linear mixed effects model, where time was modelled as fixed effect, while the individual ID was modelled as random effect. Prior to the analyses, glycan variables were all transformed to standard Normal distribution by inverse transformation of ranks to Normality (R package "GenABEL", function rntransform). Using rank transformed variables makes estimated effects of different glycans comparable, as these will have the same standardized variance. False discovery rate (FDR) was controlled by the Benjamini-Hochberg

procedure at the specified level of 0.05. Data was analysed and visualized using R programming language (version 3.5.2)(31).

TwinsUK cohort. Normalization of peak intensities to the total chromatogram area was performed for each measured sample separately. Calculated proportions were then batch corrected using ComBat method (R package *sva*)(30). After the batch correction the first 11 peaks, which predominantly originate from IgG (32), were used to calculate 6 derived glycan traits – agalactosylation (G0), monogalactosylation (G1), digalactosylation (G2), bisecting GlcNAc (B), core fucosylation (CF) and high mannose structures (HM). Mixed models were fitted to estimate the effect of BMI change on IgG N-glycome (R package *lme4*)(33). Directly measured or derived glycan trait was used as a dependent variable in the mixed model. To differentiate between BMI change and the absolute BMI value, the variable was separated to $BMI_{baseline}$ and $BMI_{difference}$ (calculated according to the following equation: $BMI_{difference} = BMI_{follow\ up\ age} - BMI_{baseline\ age}$), and both were used in the model as a fixed effect. Since IgG N-glycome is affected by aging, age was included both as a fixed effect and a random slope. Finally, to meet the independency criteria, family ID and individual ID (nested within family) were included in the model as a random intercept. Due to multiple model fitting (for 11 directly measured and 6 derived glycan traits) false discovery rate was controlled using Benjamini-Hochberg method. All statistical analyses were performed using R programming language (version 3.6.3)(31).

RESULTS

Pre-surgical low-calorie diet extensively changes plasma N-glycome

We profiled both plasma and IgG N-glycome in a cohort of bariatric surgery-candidate patients at the beginning and at the end of their pre-operative diet. We calculated corresponding derived glycan traits, which average particular glycosylation features. By employing a linear mixed model, we observed ample changes in plasma N-glycome, as 10 out of 16 calculated derived traits displayed significant alterations after the low-calorie diet. Namely, low branched (LB), agalactosylated (G0), monogalactosylated (G1), asialylated (S0), monosialylated (S1), core fucosylated (CF) and glycans bearing a bisecting GlcNAc (B) showed a substantial increase in their abundances (Table 3). Conversely, high branched (HB), trisialylated (S3) and trigalactosylated (G3) glycan abundances decreased (Table 3).

Interestingly, IgG glycome was not affected by the low-calorie diet, as its derived traits did not display any significant changes after the dieting period. Graphical representation of the longitudinal alterations in plasma N-glycome after low calorie diet are depicted in Figure 1.

Table 3 Low-calorie diet induces significant changes in plasma N-glycome. Longitudinal analysis was performed by implementing a linear mixed effects model, with time as a fixed effect and the individual sample measurement as a random effect. False discovery rate was controlled using Benjamini-Hochberg method at the specified level of 0.05.

Derived glycan trait	*Time_effect*	*Time_SE*	*Time_p-value*	*Adjusted p-value*
monogalactosylation (G1)	0.6020	0.0796	4.18×10^{-05}	6.69×10^{-04}
trisialylation (S3)	-1.1512	0.2008	3.04×10^{-04}	2.43×10^{-03}
agalactosylation (G0)	0.4903	0.0948	6.09×10^{-04}	2.44×10^{-03}
core fucosylation (CF)	0.5431	0.1011	4.73×10^{-04}	2.44×10^{-03}
high branching (HB)	-1.1925	0.2468	9.43×10^{-04}	2.52×10^{-03}
asialylation (S0)	0.6336	0.1310	9.40×10^{-04}	2.52×10^{-03}
trigalactosylation (G3)	-1.1925	0.2581	1.24×10^{-03}	2.84×10^{-03}
bisecting GlcNAc (B)	0.5457	0.1350	2.84×10^{-03}	5.69×10^{-03}
low branching (LB)	0.9839	0.3060	9.99×10^{-03}	1.78×10^{-02}
monosialylation (S1)	0.5024	0.1981	2.98×10^{-02}	4.77×10^{-02}
disialylation (S2)	-0.4314	0.1941	4.99×10^{-02}	7.25×10^{-02}
high mannose (HM)	0.7545	0.3619	6.24×10^{-02}	8.33×10^{-02}
antennary fucosylation (AF)	-0.1804	0.1102	1.28×10^{-01}	1.58×10^{-01}
digalactosylation (G2)	0.3107	0.2309	2.01×10^{-01}	2.30×10^{-01}
tetragalactosylation (G4)	-0.3446	0.3477	3.36×10^{-01}	3.58×10^{-01}
tetrasialylation (S4)	-0.3049	0.3547	4.00×10^{-01}	4.00×10^{-01}

Red – significant decrease; green – significant increase; blue – non-significant change.
GlcNAc – *N*-acetylglucosamine; SE – standard error



Figure 1 Low calorie diet-related alterations in plasma N-glycome after a 3-week follow-up. Red line – significant decrease; green line – significant increase; blue line – non-significant change.

Bariatric surgery markedly alters IgG N-glycosylation

Using the same chromatographic approach, we analysed samples from patients who underwent bariatric surgery. The plasma samples were collected on the day of surgery (month 0), approximately 6 months post-surgery and 12 months post-surgery. Both plasma and IgG N-glycans were profiled in each of these timepoints, and the obtained values were used for derived glycan traits calculations. Of the examined plasma glycosylation features, only agalactosylation (G0) displayed significant decrease after bariatric surgery (Table 4). On the other hand, IgG N-glycome showed more extensive changes, following the bariatric procedure. Namely, four out of eight tested derived traits showed marked changes: core fucosylated (CF) and agalactosylated (G0) glycans decreased, while digalactosylated (G2) and monosialylated (S1) glycans increased after the surgery (Table 4). The IgG glycans whose

abundances were increased after bariatric surgery are major components of a "young" IgG glycome, as they are typically associated with a younger age. The opposite applies to agalactosylated structures , which are usual denominators of an "old" IgG glycome profile. We also examined the correlation of patients' clinical data with plasma and IgG glycome features using multivariate analysis, but found no statistically significant associations (data not shown). Finally, the type of bariatric surgery (either sleeve gastrectomy or Roux-en-Y gastric bypass) did not affect plasma nor IgG glycome composition. Graphical representations of the longitudinal alterations in IgG and plasma glycosylation features are depicted in Figure 2 and Supplementary Figure 3, respectively.

Table 4 Bariatric surgery induces significant changes in plasma and IgG N-glycomes. Longitudinal analysis was performed by implementing a linear mixed effects model, with time as a fixed effect and the individual sample measurement as a random effect. False discovery rate was controlled using Benjamini-Hochberg method at the specified level of 0.05.

N-glycome	*Derived glycan trait*	*Time_effect*	*Time_SE*	*Time_p-value*	*Adjusted p-value*
plasma	agalactosylation (G0)	-0.0273	0.0071	5.26×10^{-04}	8.42×10^{-03}
IgG	agalactosylation (G0)	-0.0339	0.0078	9.23×10^{-05}	7.38×10^{-04}
IgG	digalactosylation (G2)	0.0275	0.0072	3.75×10^{-04}	1.50×10^{-03}
IgG	monosialylation (S1)	0.0193	0.0080	1.97×10^{-02}	3.94×10^{-02}
IgG	core fucosylation (CF)	-0.0155	0.0064	1.74×10^{-02}	3.94×10^{-02}

Red – significant decrease; green – significant increase. SE – standard error.



Figure 2 Bariatric surgery-related alterations in IgG N-glycome over time (months). Red line – significant decrease; green line – significant increase; blue line – non-significant change.

<u>Weight loss induces shift towards ''young'' IgG N-glycome</u>

Using the same chromatographic approach, we profiled plasma protein N-glycome from 1,680 TwinsUK study participants sampled at several timepoints over a 20-year-period. This served as a replication of the findings from the bariatric cohort, whose participants exhibited the reversal from ''old'' to ''young'' IgG N-glycome due to weight loss. As these results showed prominent changes in IgG composite glycan traits only, herein we focused on IgG glycosylation changes. Due to the fact that for TwinsUK cohort plasma glycome was profiled, we calculated derived traits and performed statistical analysis only on the first 11 glycan peaks, corresponding to the glycans predominantly originating from IgG (32). Six derived traits were calculated – agalactosylation (G0), monogalactosylation (G1), digalactosylation (G2), incidence of bisecting GlcNAc (B), core fucosylation (CF) and incidence of high mannose structures (HM). We examined IgG glycome alterations associated with changes in BMI using a mixed model on a subset of 3,742 samples. Out of six examined IgG glycosylation features

(derived traits), three displayed significant BMI-related changes – agalactosylation (G0), digalactosylation (G2) and incidence of high mannose structures (HM) (Table 5). Namely, the abundance of digalactosylated (G2) glycans increased with the BMI decrease, while the abundance of agalactosylated (G0) and high mannose glycans (HM) decreased with the weight loss, estimated by the BMI drop. These findings are in line with the results observed in the bariatric surgery cohort. Graphical representation of the longitudinal BMI-dependent alterations of IgG glycosylation are depicted at Figure 3.

Table 5 Longitudinally monitored weight loss results with significant changes of IgG N-glycosylation. Longitudinal analysis was performed by implementing a mixed model, fitted to estimate the effect of BMI change on IgG N-glycome. False discovery rate was controlled using Benjamini-Hochberg method at the specified level of 0.05.

Derived glycan trait	***BMI difference effect (glycan abundance (%) change per 1 kgm^{-2} decrease in BMI)***	***BMI difference SE (glycan abundance (%) change per 1 kgm^{-2} decrease in BMI)***	***p-value***	***Adjusted p-value***
digalactosylation (G2)	0.2004	0.0403	6.88×10^{-07}	5.85×10^{-06}
high mannose (HM)	-0.0519	0.0119	1.33×10^{-05}	5.66×10^{-05}
agalactosylation (G0)	-0.1048	0.0397	8.43×10^{-03}	1.79×10^{-02}
bisecting GlcNAc (B)	0.0526	0.0262	4.49×10^{-02}	6.94×10^{-02}
monogalactosylation (G1)	-0.0573	0.0343	9.53×10^{-02}	1.25×10^{-01}
core fucosylation (CF)	-0.0059	0.0285	8.36×10^{-01}	8.89×10^{-01}

Red – significant decrease; green – significant increase; blue – non-significant change.
GlcNAc – *N*-acetylglucosamine; SE – standard error



Figure 3 BMI-associated alterations in IgG N-glycosylation across multiple timepoints. Changes in IgG derived traits are presented with lineplots of hypothetical ageing of TwinsUK participants (all women). Black dot represents a starting point of a 30-year-old woman, black triangle of a 40-year-old woman and black square of a 50-year-old woman. All of these women have a baseline BMI of 25 kg m^{-2}. Blue lines represent age-related IgG glycosylation changes attributed to stabile BMI. Green lines represent age-related IgG glycosylation changes attributed to increasing BMI (0.5 kg m^{-2} per year, through a period of 10 years). Red lines represent age-related IgG glycosylation changes attributed to decreasing BMI (0.5 kg m^{-2} per year, through a period of 10 years). Highlighted areas represent 95% confidence intervals. The effect of age on IgG glycosylation is represented with the curve slope, while the effect of BMI change is represented with the distance of green/red line from the blue line.

DISCUSSION

In this study, we have observed extensive changes in both plasma and IgG N-glycome associated with weight loss following low-calorie diet and bariatric surgery, or expressed through BMI decrease. To the best of our knowledge, this is the first study to investigate

plasma and IgG N-glycome alterations in patients who underwent a low-calorie diet followed by bariatric surgery.

Prior to bariatric surgery, patients were subjected to a low-calorie diet which caused significant and extensive changes to the plasma protein N-glycome. The observed changes can be summarized as significant increase in low-branched, biantennary structures (S0, S1, G0, G1…) and, conversely, substantial decrease in high-branched, triantennary, more complex structures (S3, G3). The glycosylation alterations induced by a low-calorie diet are showing exactly the opposite direction of change than those seen in various inflammatory conditions, such as type 2 diabetes, chronic obstructive pulmonary disease and inflammatory bowel disease (16,29,34,35), suggesting a gradual attenuation of inflammation. Interestingly, no significant changes were found for the IgG N-glycome alone after the diet, probably due to the relatively short follow-up period (3 weeks), which matches IgG serum half-life. Altogether, our glycomic data suggest that the overall inflammatory body status improves after a short time of low-calorie diet, reflecting a quickly noticeable and beneficial metabolic effect.

We have analysed both plasma and IgG N-glycome from individuals who underwent bariatric surgery, in a longitudinal manner. We observed significant changes in both plasma and IgG N-glycome. In particular, plasma N-glycome showed significant alterations only in agalactosylated (G0) glycans, whose abundance decreased during the follow-up period. Since the majority of agalactosylated species in plasma originates from IgG (32), it is no surprise that this glycosylation feature was also found to be significantly decreased in IgG glycome analysis. Elevated levels of G0 IgG glycoforms are typically associated with aging, a pro-inflammatory IgG glycan profile and various inflammatory diseases (11). On the other hand, the levels of digalactosylated (G2) glycans increased after bariatric surgery and at sequential timepoints, in accordance with a reduced inflammatory potential of the circulating IgG. Interestingly, the increased levels of IgG galactosylation are associated with a younger biological age and are considered, in a way, as a measure of an individual's well-being (14). Converesely, IgG galactosylation levels substantially decrease with ageing and during inflammation (11,13). Our results demonstrate that weight loss, resulting from bariatric surgery, can initiate the reversal from an ''old'' to a ''young'' IgG N-glycome, potentially reversing the clock for the immune/biological age. Furthermore, bariatric surgery also resulted in significant IgG glycome alteration inducing a decrease in core fucosylation. The vast majority of circulating IgG

386 molecules bears core fucose (approximately 95%), which profoundly decreases IgG binding
387 affinity to FcγRIIIA receptor and sequential antibody-dependent cellular cytotoxicity (ADCC)
388 (36). ADCC is largely mediated by natural killer cells that can lyse target cells and fight viral
389 infections. This would suggest that an extensive weight loss ameliorates immune responses
390 dedicated to combat viral infections, by altering IgG glycosylation and modulating its effector
391 functions. Lastly, bariatric surgery-related weight loss led to an increase in IgG sialylation,
392 which is the main modulator of the IgG anti-inflammatory actions (37). In addition to its anti-
393 inflammatory actions, the level of IgG sialylation has been implicated in the pathogenesis of
394 obesity-induced insulin resistance and hypertension, as already mentioned (22,23). Namely,
395 inhibitory IgG receptor FcγRIIB was found to be expressed in the microvascular endothelium.
396 Sequentially, it was shown that hyposialylated IgG acts as its operating ligand, leading to the
397 induction of obesity-related insulin resistance and hypertension. On the other hand, the
398 sialylated glycoform is not activating the signalling pathways responsible for the insulin
399 resistance and hypertension development, but is rather preserving insulin sensitivity and
400 normal vasomotor tone, even in obese mice. Interestingly, the same group made another
401 significant discovery – promotion of IgG sialylation breaks the link between obesity and
402 hypertension/insulin resistance (23,24). Namely, supplementation with the sialic acid
403 precursor restored IgG sialylation, highlighting a potential approach to improve both
404 metabolic and cardiovascular health in humans, with a single intervention. Our data suggest
405 that a similar effect might be achieved by weight loss interventions, through restoring of IgG
406 sialylation levels. Altogether, it is quite fascinating that such marked effects could be observed
407 on a rather small number of participants, which further highlights their significance in a given
408 biological setting.
409
410 Lastly, in order to confirm the effects of weight loss on the biological/immune age, we
411 investigated how BMI decrease affects IgG N-glycome during a 20-year-period. We observed
412 the prominent inverse changes of agalactosylated (G0) and digalactosylated (G2) IgG glycans.
413 Namely, agalactosylated IgG glycans significantly decreased, while digalactosylated ones
414 substantially increased as the BMI decreased. These observations corroborated our earlier
415 findings, confirming that the body weight reduction reverses IgG glycome from “old” to
416 “young”, implying at the same time a likely reduction in the biological/ immune age.
417 Nonetheless, we have to acknowledge the following limitations of TwinsUK as a replication

cohort: first – TwinsUK participants have not experienced such an extensive weight loss, which potentially influenced the replication of other significant glycan changes from the bariatric cohort; second – herein, the weight loss was approximated by BMI decrease, which is usually a legitimate assumption, however, it does not have to apply to all cases; and third – herein we profiled plasma glycome, while the IgG glycan traits were only approximated and the information on IgG sialylation was confounded by other plasma glycoproteins. Ideally, these issues could be circumvented in the future studies whose experimental design would allow the simultaneous, multi-centre follow-up of larger groups of patients.

Intense physical exercise can also shift IgG N-glycome towards a ”younger” profile by increasing IgG galactosylation (25). Although another study reported that prolonged intensive exercise can have the opposite effect and promote pro-inflammatory changes of IgG N-glycome (38), its findings are not surprising since it recruited healthy, normal-weight female participants, subjected to the intense energy deprivation and exercise levels, to induce substantial fat loss in a rather short time period. The authors also highlighted that starting weight and the way in which weight loss is achieved could be crucial for the final effect on the immune system. Therefore, it seems that exercise overall has a positive impact on the immune system and biological clock, but its intensity and duration should be personalized in order to provide the optimal results.

To summarize, our results indicate that weight loss has impact on inflammation and biological aging by altering plasma and IgG N-glycosylation patterns. Glycosylation changes can be reliably quantified and used to estimate the “age” of the immune system. This could represent a valuable tool in the context of COVID-19 patient stratification. Since inter-individual variation in protein glycosylation is extensive, its functional implications on membrane expression of various proteins (including ACE2), functional properties of newly synthesized SARS-CoV-2 virus particles and regulation of the immune responses may also explain severe cases of COVID-19 in apparently healthy individuals. A previous research showed that impairment of ACE2 N-glycosylation affects its ability to allow the transduction of SARS Human coronavirus NL63 (HCoV-NL63) particles, by disrupting the viral endocytosis (39).

Future glycomic studies of patients infected with SARS- CoV-2 would help to elucidate whether ACE2 N-glycosylation differs in patients with severe COVID-19, compared to asymptomatic patients or healthy individuals.

ACKNOWLEDGMENTS

The authors thank Rachel Franklin, Michelle Haylock, James Chivenga, Roxanne Williams and Krishnageetha Manoharan for the samples collection and biobanking. The authors thank all the patients who took part in this study.

FUNDING

Glycosylation analysis was performed in Genos Glycoscience Research Laboratory and partly supported by the European Union's Horizon 2020 grants Backup (grant# 777090), European Structural and Investment Funds IRI grant (#KK.01.2.1.01.0003), Centre of Competence in Molecular Diagnostics (#KK.01.2.2.03.0006) and Croatian National Centre of Research Excellence in Personalized Healthcare grant (#KK.01.1.1.01.0010). Bariatric research was supported by the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre Gastroenterology and Mucosal Immunity Theme to CVA-C and VLG, Oxford Biomedical Research Centre Diabetes and Metabolism theme for JWT, MRC programme grant to JWT (ref. MR/P011462/1), the NIHR Research Capability Funding to VLG and AG, the Wellcome Trust (101734/Z/13/Z) to AG. NJD is supported by a University of Oxford Novo Nordisk Clinical Research Fellowship. TwinsUK received funding from the Wellcome Trust European Community's Seventh Framework Programme (FP7/2007-2013 to TwinsUK); the National Institute for Health Research (NIHR) Clinical Research Facility at Guy's & St Thomas' NHS Foundation Trust and the Nottingham NIHR Biomedical Research Centre based at Guy's and St Thomas' NHS Foundation Trust and King's College London. CM is funded by the MRC AimHy (MR/M016560/1) project grant and by the Chronic Disease Research Foundation.

AUTHOR`S CONTRIBUTION

Study design: CM, AG, CVA-C, GL. Data collection: VLG, ACv, TŠ, NJD, ACi, HD, MF, CM. Data analysis: DK, FV. Data interpretation: VLG, ACv, TŠ, NJD, DK, FV, MF, JWT, OG, TS, CM, AG, CVA-C, GL. Drafting manuscript: VG, ACv, TŠ, NJD, DK, FV, GL. Revising and approving final version of manuscript: ALL. CM, AG, CVA-C and GL take responsibility for the integrity of the data analysis

REFERENCES

1. Obesity and overweight [Internet]. [cited 2020 Apr 16]. Available from: https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight

2. Petrilli CM, Jones SA, Yang J, Rajagopalan H, O'Donnell LF, Chernyak Y, et al. Factors associated with hospitalization and critical illness among 4,103 patients with COVID-19 disease in New York City. medRxiv. 2020 Apr 11;2020.04.08.20057794.

3. Han TS, Lean ME. A clinical perspective of obesity, metabolic syndrome and cardiovascular disease. JRSM Cardiovasc Dis. 2016 Dec;5:2048004016633371.

4. Alpert A, Pickman Y, Leipold M, Rosenberg-Hasson Y, Ji X, Gaujoux R, et al. A clinically meaningful metric of immune age derived from high-dimensional longitudinal monitoring. Nat Med. 2019 Mar;25(3):487–95.

5. Franceschi C, Garagnani P, Parini P, Giuliani C, Santoro A. Inflammaging: a new immune–metabolic viewpoint for age-related diseases. Nature Reviews Endocrinology. 2018 Oct;14(10):576–90.

6. Touch S, Clément K, André S. T Cell Populations and Functions Are Altered in Human Obesity and Type 2 Diabetes. Curr Diab Rep. 2017 Sep;17(9):81.

7. Dhurandhar NV, Bailey D, Thomas D. Interaction of obesity and infections. Obes Rev. 2015 Dec;16(12):1017–29.

8. Lauc G, Sinclair D. Biomarkers of biological age as predictors of COVID-19 disease severity. Aging [Internet]. 2020 Apr 8 [cited 2020 Apr 14]; Available from: http://www.aging-us.com/article/103052/text

9. Lauc G, Pezer M, Rudan I, Campbell H. Mechanisms of disease: The human N-glycome. Biochimica et Biophysica Acta - General Subjects. 2016;1860(8):1574–82.

10. Gornik O, Pavić T, Lauc G. Alternative glycosylation modulates function of IgG and other proteins - implications on evolution and disease. Biochim Biophys Acta. 2012 Sep;1820(9):1318–26.

11. Gudelj I, Lauc G, Pezer M. Immunoglobulin G glycosylation in aging and diseases. Cellular Immunology. 2018;

12. Dall'Olio F. Glycobiology of aging. In: Subcellular Biochemistry. 2018.

13. Krištić J, Vučković F, Menni C, Klarić L, Keser T, Beceheli I, et al. Glycans Are a Novel Biomarker of Chronological and Biological Ages. The Journals of Gerontology: Series A. 2014 Jul;69(7):779–89.

14. Štambuk J, Nakić N, Vučković F, Pučić-Baković M, Razdorov G, Trbojević-Akmačić I, et al. Global variability of the human IgG glycome [Internet]. Biochemistry; 2019 Feb [cited 2020 Jan 31]. Available from: http://biorxiv.org/lookup/doi/10.1101/535237

15. Menni C, Gudelj I, MacDonald-Dunlop E, Mangino M, Zierer J, Bešić E, et al. Glycosylation Profile of Immunoglobulin G Is Cross-Sectionally Associated with Cardiovascular Disease Risk Score and Subclinical Atherosclerosis in Two Independent Cohorts. Circulation Research. 2018;122(11):1555–64.

16. Wittenbecher C, Štambuk T, Kuxhaus O, Rudman N, Vučković F, Štambuk J, et al. Plasma N-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study. Diabetes Care. 2020 Jan 7;43(3):661–8.

17. Gao Q, Dolikun M, Stambuk J, Wang H, Zhao F, Yiliham N, et al. Immunoglobulin G N-Glycans as Potential Postgenomic Biomarkers for Hypertension in the Kazakh Population. Omics. 2017;21(7):380–9.

18. Liu J, Dolikun M, Štambuk J, Trbojević-Akmačić I, Zhang J, Wang H, et al. The association between subclass-specific IgG Fc N-glycosylation profiles and hypertension in the Uygur, Kazak, Kirgiz, and Tajik populations. J Hum Hypertens. 2018 Sep;32(8–9):555–63.

19. Wang Y, Klarić L, Yu X, Thaqi K, Dong J, Novokmet M, et al. The Association Between Glycosylation of Immunoglobulin G and Hypertension: A Multiple Ethnic Cross-Sectional Study. Medicine. 2016 Apr;95(17):e3379.

20. Nikolac Perkovic M, Pucic Bakovic M, Kristic J, Novokmet M, Huffman JE, Vitart V, et al. The association between galactosylation of immunoglobulin G and body mass index. Progress in Neuro-Psychopharmacology and Biological Psychiatry. 2014 Jan;48:20–5.

21. Russell AC, Kepka A, Trbojević-Akmačić I, Ugrina I, Song M, Hui J, et al. Increased central adiposity is associated with pro-inflammatory immunoglobulin G N-glycans. Immunobiology. 2019;224(1):110–5.

22. Sundgren NC, Vongpatanasin W, Boggan BMD, Tanigaki K, Yuhanna IS, Chambliss KL, et al. IgG receptor FcγRIIB plays a key role in obesity-induced hypertension. Hypertension. 2015 Feb 21;65(2):456–62.

23. Tanigaki K, Sacharidou A, Peng J, Chambliss KL, Yuhanna IS, Ghosh D, et al. Hyposialylated IgG activates endothelial IgG receptor Fc**γ**RIIB to promote obesity-induced insulin resistance. J Clin Invest. 2018 Jan 2;128(1):309–22.

24. Peng J, Vongpatanasin W, Sacharidou A, Kifer D, Yuhanna IS, Banerjee S, et al. Supplementation with the Sialic Acid Precursor N-acetyl-D-Mannosamine Breaks the Link Between Obesity and Hypertension. 2019.

25. Tijardović M, Marijančević D, Bok D, Kifer D, Lauc G, Gornik O, et al. Intense Physical Exercise Induces an Anti-inflammatory Change in IgG N-Glycosylation Profile. Frontiers in Physiology. 2019;10(December):1–10.

26. Nguyen NT, Kim E, Vu S, Phelan M. Ten-year Outcomes of a Prospective Randomized Trial of Laparoscopic Gastric Bypass Versus Laparoscopic Gastric Banding. Ann Surg. 2018;268(1):106–13.

27. O'Brien P. Bariatric surgery and type 2 diabetes: a step closer to defining an optimal approach. The Lancet Diabetes & Endocrinology. 2019 Dec 1;7(12):889–91.

28. Verdi S, Abbasian G, Bowyer RCE, Lachance G, Yarand D, Christofidou P, et al. TwinsUK: The UK Adult Twin Registry Update. Twin Res Hum Genet. 2019 Dec;22(6):523–9.

29. Pavić T, Dilber D, Kifer D, Selak N, Keser T, Ljubičić Đ, et al. N-glycosylation patterns of plasma proteins and immunoglobulin G in chronic obstructive pulmonary disease. J Transl Med. 2018 Nov 21;16.

30. Leek JT, Johnson WE, Parker HS, Jaffe AE, Storey JD. The sva package for removing batch effects and other unwanted variation in high-throughput experiments. Bioinformatics. 2012 Mar 15;28(6):882–3.

31. R Core Team (2020). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. URL https://www.R-project.org/.

32. Clerc F, Reiding KR, Jansen BC, Kammeijer GSM, Bondt A, Wuhrer M. Human plasma protein N-glycosylation. Glycoconj J. 2016 Jun 1;33(3):309–43.

33. Bates D, Mächler M, Bolker B, Walker S. Fitting Linear Mixed-Effects Models Using lme4. Journal of Statistical Software. 2015 Oct 7;67(1):1–48.

34. Clerc F, Novokmet M, Dotz V, Reiding KR, de Haan N, Kammeijer GSM, et al. Plasma N-Glycan Signatures Are Associated With Features of Inflammatory Bowel Diseases. Gastroenterology. 2018;155(3):829–43.

35. Novokmet M, Lukić E, Vučković F, –Durić Ž, Keser T, Rajšl K, et al. Changes in IgG and total plasma protein glycomes in acute systemic inflammation. Scientific Reports. 2014 Mar 11;4(1):1–10.

36. Iida S, Kuni-Kamochi R, Mori K, Misaka H, Inoue M, Okazaki A, et al. Two mechanisms of the enhanced antibody-dependent cellular cytotoxicity (ADCC) efficacy of non-fucosylated therapeutic antibodies in human blood. BMC Cancer. 2009 Feb 18;9:58.

37. Kaneko Y, Nimmerjahn F, Ravetch JV. Anti-Inflammatory Activity of Immunoglobulin G Resulting from Fc Sialylation. Science. 2006 Aug 4;313(5787):670–3.

38. Sarin HV, Gudelj I, Honkanen J, Ihalainen JK, Vuorela A, Lee JH, et al. Molecular Pathways Mediating Immunosuppression in Response to Prolonged Intensive Physical Training, Low-Energy Availability, and Intensive Weight Loss. Front Immunol. 2019;10:907.

39. Zhao X, Guo F, Comunale MA, Mehta A, Sehgal M, Jain P, et al. Inhibition of endoplasmic reticulum-resident glucosidases impairs severe acute respiratory syndrome coronavirus and human coronavirus NL63 spike protein-mediated entry by altering the glycan processing of angiotensin I-converting enzyme 2. Antimicrob Agents Chemother. 2015 Jan;59(1):206–16.

590